

Applicant : Paul Andrew Wi al.
Serial No. : Unassigned
Filed : Herewith
Page : 3

Attorney's Docket No. 06275-247US1 / A2239-1P US

REMARKS

Amendments to the claims have been made to remove multiple dependency while conserving the claimed subject matter. No new matter has been added.

Attached is a marked-up version of the changes being made by the current amendment.

Claims 1 to 19 are now pending. Applicants submit that all of the claims are now in condition for examination, which action is requested.

Applicants ask that all claims be examined. Please apply any charges or credits to Deposit Account No. 06-1050. referencing Attorney Docket No. 06275-247US1.

Respectfully submitted,

Date:

March 29, 2002

Janis K. Fraser, Ph.D., J.D.
Reg. No. 34,819

Fish & Richardson P.C.
225 Franklin Street
Boston, Massachusetts 02110-2804
Telephone: (617) 542-5070
Facsimile: (617) 542-8906

Version with markings to show changes made

In the claims:

Claims 3, 10-14, 16, and 17 have been amended as follows:

-- 3. (Amended) A compound according to [claim 1 or claim 2] claim 1, wherein one of R² and R³ is hydrogen and the other is C₁-C₈ alkyl substituted by hydroxy.

10. (Amended) A pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in [any one of claims 1 to 6] claim 1, in association with a pharmaceutically acceptable adjuvant, diluent or carrier.

11. (Amended) A process for the preparation of a pharmaceutical composition [as claimed in claim 10] which comprises mixing a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in [any one of claims 1 to 6] claim 1, with a pharmaceutically acceptable adjuvant, diluent or carrier.

12. (Amended) A compound of formula (I), or a pharmaceutically-acceptable salt or solvate thereof, as claimed in [any one of claims 1 to 6] claim 1, for use in therapy.

13. (Amended) Use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in [any one of claims 1 to 6] claim 1, in the manufacture of a medicament for use in therapy.

14. (Amended) A method of treating a chemokine mediated disease wherein the chemokine binds to one or more chemokine receptors, which comprises administering to a patient a therapeutically effective amount of a compound of formula (I), or a

20250723 10:23:00

Applicant : Paul Andrew Wi al.
Serial No. : Unassigned
Filed : Herewith
Page : 5

Attorney's Docket No. 6275-247US1 / A2239-1P US

pharmaceutically acceptable salt or solvate thereof, as claimed in [any one of claims 1 to 6] claim 1.

16. (Amended) A method according to [claim 14 or 15] claim 14 in which the chemokine receptor is the CXCR2 receptor.

17. (Amended) A method of treating an inflammatory disease in a patient suffering from, or at risk of, said disease, which comprises administering to the patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in [any one of claims 1 to 6] claim 1. --

11/11/2014 10:00:00 AM